openPR Logo
Press release

Novartis "PIQRAY® (alpelisib) market size expected to increase many folds by 2032, report DelveInsight

04-02-2024 08:53 PM CET | Health & Medicine

Press release from: DelveIinsight Business Research

Novartis "PIQRAY® (alpelisib) market size expected

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on PIQRAY (Novartis) providing insights into the drug market landscape and market forecast of PIQRAY upto 2032. The report, titled "PIQRAY Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.

Are you interested in finding out the projected market size of PIQRAY in 2032? PIQRAY Market Forecast
https://www.delveinsight.com/report-store/piqray-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

The PIQRAY Market Report offers projected sales forecasts for PIQRAY for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Novartis's PIQRAY is serving as a beacon of hope for the patients suffering from the ER+ve HER2-ve Breast Cancer.

What is a PIQRAY Prescribed for?
PIQRAY is a type of kinase inhibitor used alongside fulvestrant for treating advanced or metastatic breast cancer in adults. This type of cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and exhibit a mutation in the PIK3CA gene, as confirmed by an FDA-approved test, after progression on or after prior endocrine therapy.

The report extensively covers the details and developments related to PIQRAY, capturing important highlights on developmental pipeline, regulatory status and special designations of PIQRAY, route of administration, safety and efficacy details.

PIQRAY Market Assessment
This report provides a detailed market assessment of PIQRAY for ER+ve HER2-ve Breast Cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

PIQRAY Clinical Assessment
The report provides the clinical trials information of PIQRAY for ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against PIQRAY? PIQRAY Drugs Insights
https://www.delveinsight.com/sample-request/piqray-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PIQRAY Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the PIQRAY.

PIQRAY Market Size in the US
A dedicated section of the report focuses on the expected market size of PIQRAY for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of PIQRAY:

• The report contains forecasted sales of PIQRAY for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for PIQRAY in ER+ve HER2-ve Breast Cancer.
Stay ahead in competition by leveraging insights on PIQRAY market Report: Download PIQRAY Market Report
https://www.delveinsight.com/sample-request/piqray-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy PIQRAY Market Report:
• The report provides future market assessments for PIQRAY for ER+ve HER2-ve Breast Cancer in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading PIQRAY for ER+ve HER2-ve Breast Cancer forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PIQRAY
• Discover the competitive landscape of PIQRAY through 7MM
• Get a Thorough Analysis of the PIQRAY Development pipeline, Safety & Efficacy of the PIQRAY, and ROA
• Thorough PIQRAY market forecast will help understand how drug is competing with other emerging PIQRAY
• Get analysis of the PIQRAY clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

ER+ve HER2-ve Breast Cancer Pipeline https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "ER+ve HER2-ve Breast Cancer Pipeline Insight, 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+ve HER2-ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key ER+ve HER2-ve Breast Cancer companies in the market include - BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Latest Reports Offered By DelveInsight:

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novartis "PIQRAY® (alpelisib) market size expected to increase many folds by 2032, report DelveInsight here

News-ID: 3449770 • Views:

More Releases from DelveIinsight Business Research

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera Biosciences, Inc, Merck Sharp & Dohme LLC
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotech
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market. The PCSK9
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsight Report | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt, Cali Pharma
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Bunion

All 5 Releases


More Releases for PIQRAY

PI3K Inhibitors Market Outlook: Roche, Novartis, and Emerging Biotechs Drive Com …
DelveInsight's comprehensive analysis reveals robust growth potential in the PI3K inhibitors market across 7MM through 2034. Key players include Roche/Genentech (ITOVEBI), Novartis (PIQRAY), Gilead Sciences (ZYDELIG), Kazia Therapeutics (Paxalisib), Celcuity (Gedatolisib), and others, with expanding applications from hematological to solid tumor indications driving market momentum. PI3K Inhibitor Key Takeaways * PI3K Inhibitor market size projection: As per DelveInsight's analysis, the total market size of PI3K inhibitors in the 7MM is expected to
Metastatic HR+/HER2 Breast Cancer Market: Epidemiology, Pipeline Products, Compa …
The total HR+/HER2- breast cancer market size in the 7MM was nearly USD 10 billion in 2023, which is expected to grow by 2034 with the launch of potential emerging therapies, assisted by an increase in the HR+/HER2- breast cancer patient pool. Emerging therapies for Metastatic HR+/HER2 Breast Cancer, including KISQALI (ribociclib), PIQRAY (alpelisib), ARV-471 (vepdegestrant), OP1250 (palazestrant), and others, are anticipated to drive significant growth in the Metastatic HR+/HER2 Breast
Metastatic HR+/HER2- Breast Cancer Market: Analysis of Epidemiology, Pipeline Pr …
Metastatic HR+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), PIQRAY (alpelisib), ARV-471 (vepdegestrant), OP1250 (palazestrant), and others are expected to boost the Metastatic HR+/HER2- Breast Cancer Market in the upcoming years. DelveInsight has launched a new report on "Metastatic HR+/HER2- Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Metastatic HR+/HER2- Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HR+/HER2-
3 Phosphoinositide Dependent Protein Kinase 1 Market Outlook 2029: Presents Mark …
The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period. PDK1 or 3-Phosphoinositide-dependent kinase 1 is a key member of the AGC protein kinase family and is important in a variety of cellular functions which leads to the activation of the PI3K signalling pathway which is an event that is associated with the onset and progression of several human
HR Positive/ HER2 Negative Breast Pipeline Assessment (2023) Covering Clinical T …
Las Vega (Nevada), United States //- "HR Positive/ HER2 Negative Breast Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the HR Positive/ HER2 Negative Breast Therapeutics Market. The report provides a detailed description of the HR Positive/ HER2 Negative Breast drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products,
3 Phosphoinositide Dependent Protein Kinase 1 Market Overview by Recent Opportun …
The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). PDK1 or 3-Phosphoinositide-dependent kinase 1 is a key member of the AGC protein kinase family and is important in a variety of cellular functions which leads to the activation of the PI3K signalling pathway which is an event that is associated with the onset and progression of several